Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo.
about
Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantationThe immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpointsLymphocyte-activation gene-3, an important immune checkpoint in cancerExpanding the antimalarial toolkit: Targeting host-parasite interactionsBeyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint RegulatorsHigh avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairmentCancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection.LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3Lymphocyte activation gene-3 expression defines a discrete subset of HIV-specific CD8+ T cells that is associated with lower viral loadTwo genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis.The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells.IL-35-mediated induction of a potent regulatory T cell population.PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in miceClinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.Expression of a broad array of negative costimulatory molecules and Blimp-1 in T cells following priming by HIV-1 pulsed dendritic cells.LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cellsCoregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.LAG-3 regulates plasmacytoid dendritic cell homeostasisCD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2Differential Regulation of the Immune Response in the Spleen and Liver of Mice Infected with Leishmania donovani.Metalloproteases regulate T-cell proliferation and effector function via LAG-3Lung CD8+ T Cell Impairment Occurs during Human Metapneumovirus Infection despite Virus-Like Particle Induction of Functional CD8+ T Cells.Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.The battle against immunopathology: infectious tolerance mediated by regulatory T cells.Inhibitory receptors as targets for cancer immunotherapyModulation of redox balance leaves murine diabetogenic TH1 T cells "LAG-3-ing" behind.LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer modelLAG-3 in Cancer Immunotherapy.Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion.Costimulatory and Coinhibitory Receptor Pathways in Infectious DiseaseProgression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes.The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses.Programmed death 1 regulates development of central memory CD8 T cells after acute viral infection.Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections.Increasing LAG-3 expression suppresses T-cell function in chronic hepatitis B: A balance between immunity strength and liver injury extent.
P2860
Q21132345-4180E236-6AD6-400C-8264-B0A6C818E978Q26745842-57E51EF0-2D31-487E-8EB2-205DE3D10A8BQ26746209-D2E7AF70-6100-405E-908E-7FB185DFBF37Q26772866-19C28794-874D-4CA4-8842-1CDC06E0D47FQ26782799-213D72D5-5BDB-4749-A6B0-C9820D161475Q28729034-E9775847-3FC0-42EE-A517-EE0D00CAB015Q33731047-341959CD-31DD-4A42-8EAD-92C5976961AAQ33842859-49D5F0F1-CD95-4A0E-8A10-F91F0A5F47E6Q34093225-B9F2E8E9-4984-409C-953E-08D3E7437EDAQ34172252-10C7D895-7C02-4F99-A598-2BAC8ED236E1Q34211374-E5FC9AB1-04C1-446F-A3BC-C684C3D959E0Q34381879-96DA5371-24AC-4B80-A87B-3C52720A850AQ34388729-6D6EC676-887C-4D2E-ABF5-BCD24676B37AQ34417483-E9585DA7-3871-4338-B0BC-5D0AD7DE3AC6Q34428196-851B3FBE-529C-4743-A04B-A8EF8989DFC6Q34432872-82FCADDB-5809-46F7-BE28-54262B062AB2Q34577678-8F51BF90-3E11-446C-8FAE-31DC316660F3Q34658452-707CE43A-A86A-4C68-87C5-852F701EF7CAQ34699537-E74E3F6D-F2BD-47A0-B7A2-75D654013E7BQ34700552-A842E6F3-5854-4447-925A-488098B247A2Q34856800-8DCE3595-AADB-4D99-96EF-40BA6A7E7C9BQ34891171-1BF7F69C-29F9-4AAE-91D4-9C896F2B1772Q34939924-CD6BE1AB-94FA-43DC-856D-8618EEF62C83Q34996431-00559484-1803-44D8-9464-6955C5A13E12Q35127522-6F55D80C-777D-425F-9CEB-7895601E2B1BQ35612460-31894FA0-8CC2-4BA9-955D-645F904229ACQ35913925-6C46DDFE-4A97-47E4-94A6-F8B0914E24C6Q35934137-C9771B33-4A8C-4AB4-A7A8-C089199FD752Q35962634-CE7FC912-7220-47DD-BC00-E7F050FC55B4Q35995373-028F0555-D754-4891-9AAB-EFB6EDC44CADQ36047584-8F97EC01-6FB8-4541-8772-FA3397F79BC8Q36413772-956EF87A-B56E-4DDD-AA4A-EC089A865FB8Q36416383-8833AD62-0FC4-4363-8A9D-F40A218AE4B6Q36801213-771448D2-1B33-438D-BF8E-FC9005C2A890Q36919711-46470E4B-568E-4F0D-952E-12DA0EA77028Q37269077-115E6034-A329-4717-BE4C-F15264187D81Q37287296-340B9882-338B-4698-8339-AB6F0CC651F9Q37372772-81080ED3-2E23-491C-928B-2490395FC301Q37474904-F6B04577-B64F-4750-98C5-F5D01DD5AF44Q37582541-CE2BA0E2-94BF-49BC-8D33-BD6CE3A16E01
P2860
Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Lymphocyte activation gene-3 ( ...... ng antigen activation in vivo.
@ast
Lymphocyte activation gene-3 ( ...... ng antigen activation in vivo.
@en
Lymphocyte activation gene-3
@nl
type
label
Lymphocyte activation gene-3 ( ...... ng antigen activation in vivo.
@ast
Lymphocyte activation gene-3 ( ...... ng antigen activation in vivo.
@en
Lymphocyte activation gene-3
@nl
prefLabel
Lymphocyte activation gene-3 ( ...... ng antigen activation in vivo.
@ast
Lymphocyte activation gene-3 ( ...... ng antigen activation in vivo.
@en
Lymphocyte activation gene-3
@nl
P2093
P1476
Lymphocyte activation gene-3 ( ...... ng antigen activation in vivo.
@en
P2093
Creg J Workman
Dario A A Vignali
David L Woodland
In-Jeong Kim
Linda S Cauley
Marcia A Blackman
P304
P356
10.4049/JIMMUNOL.172.9.5450
P407
P577
2004-05-01T00:00:00Z